Overview of Investor Relations Capabilities
This presentation is the property of its rightful owner.
Sponsored Links
1 / 28

Overview of Investor Relations Capabilities PowerPoint PPT Presentation


  • 81 Views
  • Uploaded on
  • Presentation posted in: General

Overview of Investor Relations Capabilities. Rx COMMUNICATIONS. Specialists in the life science and healthcare industries Partner-driven -- Senior level counsel on EVERY account Partners have been through up and down market cycles, various political healthcare agendas and technology trends.

Download Presentation

Overview of Investor Relations Capabilities

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Overview of investor relations capabilities

Overview of Investor Relations Capabilities


Rx communications

Rx COMMUNICATIONS

  • Specialists in the life science and healthcare industries

  • Partner-driven -- Senior level counsel on EVERY account

  • Partners have been through up and down market cycles, various political healthcare agendas and technology trends


Rx communications1

Rx COMMUNICATIONS

  • Experience with private and public companies – domestic and international

  • Focused on what we do best: Investor Relations and Financial Media Relations

  • Strong Wall Street and media contacts

  • Headquartered in New York City


Private companies

PRIVATE COMPANIES

Services for Private Companies


Why embark on an ir pr program as a private company

WHY EMBARK ON AN IR/PR PROGRAM AS A PRIVATE COMPANY?

  • Lay the groundwork for future financings and eventual IPO

  • Assist with partnering activities by building corporate awareness

  • Build awareness of disease indications to generate product interest

  • Align company with reputable bankers

  • Become accustomed to working within disclosure rules i.e.; Reg FD


Providing value to private companies

PROVIDING VALUE TO PRIVATE COMPANIES

  • Develop key messages positioned for analysts and investors

  • Develop collateral materials to tell story integrating key messages

  • Target and facilitate introductions to venture capitalists and institutional investors

  • Target and advise on corporate finance team

  • Target and facilitate introductions to sell-side analysts


Providing value to private companies1

PROVIDING VALUE TO PRIVATE COMPANIES

  • Build presence on the web

  • Develop story ideas for the media

  • Cultivate reporter interest

  • Introduce to conference circuit

  • Properly position company news

  • Develop company disclosure policy


Activities surounding ipo

ACTIVITIES SUROUNDING IPO

  • Assist in the selection of banking team – beginning of quiet period

  • Press release announcing registration for offering

  • Develop roadshow presentation

  • Supplement banker’s list of target institutions

  • Presentation training


Activities surrounding ipo

ACTIVITIES SURROUNDING IPO

  • “Teach-ins” at banks

  • Roadshow

  • Press release announcing completion of IPO

  • “Welcome letter” to new shareholders

  • Create disclosure policy

  • Quiet period lasts for 25 days following the close of IPO


Public companies

PUBLIC COMPANIES

Services for Public Companies


After market support

AFTER-MARKET SUPPORT

  • Need for continual dialogue with shareholders

  • On-going targeting of investors for future financings

  • Increase analyst coverage beyond banking support

  • Fulfill disclosure requirements

  • Crisis communications

  • Strategic media out-reach


Getting started first steps

GETTING STARTED: FIRST STEPS

  • Strategy session in order to immerse ourselves in corporate story

  • Define key message points

  • Understand perceptions existent in the marketplace

  • Create targeted list of sell-side analysts, venture capitalists and fund managers


Getting started first steps1

GETTING STARTED: FIRST STEPS

  • Review collateral materials

  • Create VIP blast e-mail/fax lists

  • Develop media lists

  • Design action plan


Rx communications capabilities

Rx COMMUNICATIONS CAPABILITIES

  • Strategic Counsel

  • Roadshows

  • Analyst Contact

  • Investor Targeting

  • Investment and Industry Conferences

  • Follow-up and Analysis to Key Events

  • Press Release Writing

  • News Conferences/Press Briefings

  • Video/Radio News Releases

  • Fact Sheets

  • Annual Reports


Rx communications capabilities1

Rx COMMUNICATIONS CAPABILITIES

  • Crisis Communications

  • Mergers and Acquisitions

  • Positioning Strategy

  • Perception Audits

  • Conference Calls

  • Presentation Training

  • Placement Strategy

  • Financial, Trade and Local Media Contacts

  • Slide Presentations

  • Web Site Development


The rx team

THE Rx TEAM

Melody A. Carey, Co-President

  • Founded Rx in 2000

  • Head of Corporate Communications and Spokesperson, Schein Pharmaceutical, Inc.

  • Director of Investor Relations,

    The Multicare Companies, Inc.

  • Executive, Noonan/Russo Communications

  • Former healthcare/life sciences investment banker, Kidder, Peabody & Co.


The rx team1

THE Rx TEAM

Rhonda Chiger, Co-President

  • Founded Rx in 2000

  • Senior Managing Director, Global Consulting Practice, Thomson Financial

  • Managed Life Sciences departments for Noonan/Russo and Dewe Rogerson

  • Established London office for healthcare investor relations firm

  • Former Manager, Investor Relations, American Stock Exchange


The rx team2

The Rx Team

Eric Goldman, Vice President

  • 25 years experience in public relations and as a media relations strategist specializing in biotechnology, healthcare, technology and consumer products

  • Senior Director and Vice President at GlobalFluency

  • Handled media relations at Spector & Associates and Brouillard Communications, a division of J. Walter Thompson

  • Earned 2 Silver Anvil awards for public relations excellence


The rx team3

THE Rx TEAM

Paula B. Schwartz, Senior Vice President

  • Former Partner, FRB/Weber Shandwick, oldest and largest Investor Relations firm in the U.S.

  • Former Vice President, ECOM Consultants, Inc., an investor relations firm

  • Former Vice President/Director of Investor Relations Programs, KCS&A Public Relations, a public relations and investor relations consultancy


Rx communications current client list

Rx COMMUNICATIONS CURRENT CLIENT LIST

  • ADMA Biologics, Inc. (Private)

  • Alexandria Real Estate Equities, Inc. (NYSE: ARE)

  • Alexion Pharmaceuticals Inc. (Nasdaq: ALXN)

  • Bio-Path Holdings, Inc. (OTCQX: BPTH)

  • Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX)

  • Complix NV (Private)

  • Galena Biopharma, Inc. (Nasdaq: GALE)

  • Intact Medical Corporation (Private)


Rx communications current client list1

Rx COMMUNICATIONS CURRENT CLIENT LIST

  • MAXIMUS, Inc. (NYSE: MMS)

  • MolMedS.p.A. (Milan: MLM)

  • Neovacs, SA (Alternext Paris: ALNEV)

  • Omthera Pharmaceuticals, Inc. (Private)

  • PDI, Inc. (Nasdaq: PDII)

  • TetraLogic Pharmaceuticals (Private)

  • Theratechnologies (TSX: TH)


Ourx successes

OURx SUCCESSES

Helped to grow Alexion Pharmaceuticals’ institutional shareholder base from 30% in 1996 to approximately 95% today.

Launched not-for-profit Immune Tolerance Institute resulting in broad coverage in the U.S. including CBS Radio Network, San Francisco Business Times and Drug Discovery News

Garnered coverage for Catalyst Pharmaceutical Partners’ compound for cocaine addiction. Placements included cover stories in Newsweek, Scientific American Mind and NeuroInvestment


Ourx successes1

OURx SUCCESSES

Designed and implemented IR program for American CareSource Holdings which led the company to be ranked as the number one stock performer on The NASDAQ Capital Market for 2008.

An aggressive investor outreach campaign on behalf of Genaissance Pharmaceuticals allowed Genaissance to regain compliance with Nasdaq’s $1 listing rule requirement.

Guided Kos Pharmaceuticals through a failed marketing alliance which caused over two million shares to trade (four times the average daily trading volume) and the stock never dropped below 2%.


Ourx successes2

OURx SUCCESSES

Arranged feature coverage focused on Hodgkins and non-Hodgkins lymphoma for MethylGene with Genetic Engineering News, Pink Sheet, BioCentury and Pharmawire

Guided ABIOMED on issues management surrounding FDA panel meeting. Put FDA’s request for additional data into perspective with reporters and investors. CNBC interview key part of strategy.

Implemented aggressive IR program for PharmAthene, Inc. which enabled the company to obtain coverage from two new sell-side analysts, garner investments from four new institutional funds and increase trading volume by three-fold within nine months.


Ourx successes3

OURx SUCCESSES

Rx Communications was named

Best Small PR Agency

byLeague of American Communications Professionals

We are pleased to announce that Rx

Communications has been selected by PR Week

as a finalist for

Boutique PR Agency of the Year

Rx Communications Group was honored with the 2008

Stevie Award for Best Investor Relations Program

for work on behalf of specialty

pharmaceutical company, NexMed, Inc.


Ourx successes4

OURx SUCCESSES

We are also pleased to share that our work for

ImpactRx has won an Honorable Mention

Award in LACP’s (League of American

Communications Professionals) 2002 Publicity

Campaign Competition.

Rx Communications was honored with the 2002 SABRE

Awards Certificate of Excellence for Building a North

American Investor Base for client Syngenta AG.

Rx Communications received an honorable Mention

Award from PR News, as part of the PR News Platinum PR

Awards 2003. The award was issued in the

Financial/Investor Relations category, for the company's

work on behalf of Genaissance Pharmaceuticals, Inc.


Why rx communications

WHY Rx COMMUNICATIONS?

  • Specialist industry knowledge and expertise

  • Personal attention from Rx partners

  • Decades of experience in strategic counsel and implementation of financial public relations programs

  • Unique niche in working with private companies

  • Well versed in IPOs, secondary offerings, PIPEs, venture rounds and mergers and acquisitions

  • “The Street” knows and trusts us


Overview of investor relations capabilities

For Additional Information:

Rx Communications Group, LLC

445 Park Avenue

10th Floor

New York, NY 10022

(917) 322-2568

www.RxIR.com


  • Login